Understanding the transcriptome to treat KRAS-driven tumors: how far can we get?
Speaker: Silve Vicent Cambra
Center for Applied Medical Research (CIMA) [Pamplona]
Host: Eugenio Santos
Salón de actos del Centro de Investigación del Cáncer
In lung cancer and in intestinal-tract tumors such as pancreatic cancer, colorectal cancer and cholangiocarcinoma, KRAS is the most widely mutated gene and an undisputable therapeutic target. Unfortunately, the vast majority of mutant KRAS-driven cancers remain refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative strategies to neutralize KRAS-mediated effects. In this seminar I will describe the identification of central transcriptional nodes with functional relevance to KRAS oncogenesis as well as the discovery of transcriptional signatures that set the ground to unveil new therapeutic strategies to treat mutant KRAS tumors.